Gao Jian, Lu Jin-Chun, Huang Yu-Feng
PLA Research Institute of Clinical Laboratory Medicine, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
Zhonghua Nan Ke Xue. 2009 Jan;15(1):60-4.
Herpes simplex virus (HSV) infection can cause severe recurrent disease in humans and establish lifelong latency in the host. Furthermore, it can significantly increase the risk of HIV infection and bring substantial psychosexual as well as physical morbidity to the patients. Several antiviral therapies are available for the control of its symptoms and spreading, but they can neither cure nor alter the nature of HSV infection. The development of an efficacious HSV vaccine is therefore necessitated for controlling the occurrence, transmission and recurrence of the infection. Those that have undergone clinical evaluation include subunit vaccines, attenuated live virus vaccines, replication defective virus vaccine, naked DNA vaccines and viral vector vaccines. Most of the above vaccine strategies have elicited protective immunity in animal models, but none has yet been effective in human beings. For all that, scholars have never stopped their exploration for an effective vaccine against the notorious virus. The authors present an overview of a few most promising candidate vaccines for the prevention and treatment of HSV infection.
单纯疱疹病毒（HSV）感染可导致人类严重的复发性疾病，并在宿主体内建立终身潜伏感染。此外，它会显著增加感染HIV的风险，并给患者带来严重的性心理及身体方面的发病情况。目前有几种抗病毒疗法可用于控制其症状和传播，但它们既不能治愈HSV感染，也无法改变其感染性质。因此，开发一种有效的HSV疫苗对于控制感染的发生、传播和复发是必要的。那些已经接受临床评估的疫苗包括亚单位疫苗、减毒活病毒疫苗、复制缺陷病毒疫苗、裸DNA疫苗和病毒载体疫苗。上述大多数疫苗策略在动物模型中都引发了保护性免疫，但尚无一种在人类中有效。尽管如此，学者们从未停止对针对这种臭名昭著病毒的有效疫苗的探索。作者概述了几种最有前景的用于预防和治疗HSV感染的候选疫苗。
